A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

NCT07298421 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderately to Severely Active Crohns Disease

Interventions

DRUG: Afimkibart

Sponsor

Hoffmann-La Roche